Q-omics provides the consensus-scored ZNRD1ASP profile across patient tissues and cancer cell-line models. ZNRD1ASP expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, ZNRD1ASP is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ZNRD1ASP RNA expression shows 21,845 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight READ, THCA, and THYM as cancer lineages where ZNRD1ASP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNRD1ASP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNRD1ASP survival associations across molecular data types. ZNRD1ASP RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNRD1ASP RNA expression–survival associations across cancer types. High ZNRD1ASP expression shows unfavorable associations in COAD, but favorable associations in READ, PAAD, BLCA, HNSC and UCS. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for ZNRD1ASP RNA expression.
This table summarizes ZNRD1ASP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNRD1ASP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNRD1ASP shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, BLCA, COAD and HNSC. The THCA box plot shows higher ZNRD1ASP RNA expression in normal versus tumor tissue (log2 FC = −0.304, t-test p < 0.001).
This table shows molecular features associated with ZNRD1ASP in patient tissues and cancer cell lines. In patient samples, ZNRD1ASP shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
